+ 0.89
+ 0.26%
+ 0.07
+ 0.02%
+ 0.75
+ 0.18%

Why Is It Moving? Analyzing The Upward Movement in Aeterna Zentaris's Stock Today

April 26, 2021 1:30 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More

Aeterna Zentaris’s Stock Price And Volume Action

Aeterna Zentaris’s (NASDAQ:AEZS) stock is trading up 16.54% to a price of $1.09. The stock’s volume is currently 7.78 million, which is roughly 83.1% of its recent 30-day volume average of 9.36 million.

Why It’s Moving

Benzinga Pro’s real-time breaking news service shows some insight into what is affecting shares: Aeterna Zentaris shares are trading higher. Not seeing any company-specific news to justify the price action.

Insights On Recent Price Action

The moving average price of the stock over the past 50 days was $1.18 at the time this article was published. In the past fifty-two weeks, the stock price has been as high as $3.62 and as low as $0.29.

Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Trading Ideas

Related Articles

Analyzing The Price Action In AEterna Zentaris Stock Today

The Price And Volume Action In AEterna Zentaris's Stock Today AEterna Zentaris's (NASDAQ:AEZS) stock is trading up 13.13% to a price of $1.32. The stock's current volume for the day is 13.39 million, which is approximately 47.83% of its previous 30-day average volume of 27.99 million. read more

58 Biggest Movers From Yesterday

Gainers read more

38 Stocks Moving In Monday's Mid-Day Session

Gainers read more

21 Stocks Moving in Monday's Pre-Market Session

Gainers Ocugen, Inc. (NASDAQ: OCGN) shares rose 20.6% to $11.61 in pre-market trading. Ocugen’s COVID-19 vaccine partner, India-based Bharat Biotech International Ltd., will charge as much as double its main rival AstraZeneca for its vaccines in India. read more